Neuropathy in Waldenstrm's Macroglobulinemia: Pathophysiology, Prognosis and Treatment

What this Trial Is About

Neuropathy greatly impacts patients by causing sensory loss, chronic pain, and difficulty moving arms and legs. This research focuses on neuropathy linked to Waldenstrm's Macroglobulinemia (WM), a specific lymphoma type involving abnormal B cells and IgM protein. WM-related neuropathy varies widely, from mild symptoms to severe loss of movement and pain. Early treatment of WM may slow disease and nerve damage, but identifying neuropathy caused by WM versus other reasons can be challenging. The study is a cross-sectional observational design aiming to find how common neuropathy is among WM patients and to understand its clinical subtypes and underlying mechanisms. Researchers will use questionnaires, neurological exams, nerve conduction studies, blood tests, and cerebrospinal fluid analysis to investigate patients. About 90 patients with symptoms of neuropathy associated with WM will be clinically examined and tested over one year, with a three-year follow-up period. Participants will complete questionnaires and undergo physical and paraclinical assessments including nerve conduction studies and sample collections. Blood tests will analyze markers related to neuropathy, inflammation, and infections, while cerebrospinal fluid will be tested for related proteins and cells. The study will measure how many WM patients have neuropathy and assess the disability caused by it. Data will help improve diagnosis, monitoring, and treatment approaches to maintain patient mobility and quality of life.

This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic Process